Summary of COVID-19 apilimod studies
Hide extended summaries
RCT 142 COVID-19 patients showing no significant differences with apilimod treatment.
Apr 2021, NCT04446377, https://clinicaltrials.gov/study/NCT04446377, https://c19p.org/young3
1. Young et al., A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19
142 patient apilimod early treatment RCT: 199% higher mortality (p=1), 100% higher combined mortality/hospitalization (p=1), and 109% worse recovery (p=0.43).RCT 142 COVID-19 patients showing no significant differences with apilimod treatment.
Apr 2021, NCT04446377, https://clinicaltrials.gov/study/NCT04446377, https://c19p.org/young3
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.